MCID: GRV001
MIFTS: 61

Graves' Disease

Categories: Endocrine diseases, Immune diseases, Rare diseases

Aliases & Classifications for Graves' Disease

MalaCards integrated aliases for Graves' Disease:

Name: Graves' Disease 12 76 53 25 15
Graves Disease 12 25 37 29 55 44 15 73
Exophthalmic Goiter 12 53 25
Toxic Diffuse Goiter 25 73
Basedow's Disease 12 25
Basedow Disease 53 25
Autoimmune Hyperthyroidism 25
Toxic Multinodular Goiter 73
Graves' Hyperthyroidism 53
Grave's Disease 12
Parry Disease 53

Classifications:



External Ids:

Disease Ontology 12 DOID:12361
ICD10 33 E05.0
MeSH 44 D006111
NCIt 50 C3071
SNOMED-CT 68 38591003 55807009
KEGG 37 H00082

Summaries for Graves' Disease

NIH Rare Diseases : 53 Graves' disease is an autoimmune disorder that leads to overactivity of the thyroid gland (hyperthyroidism). It is caused by the immune system mistakenly attacking the thyroid gland, causing the gland to produce too much thyroid hormone. Graves disease is the most common cause of hyperthyroidism and occurs most often in women over age 20. However, the disorder may occur at any age and can affect males as well. More common signs and symptoms of hyperthyroidism due to Graves' disease include irritability, a fast and irregular heartbeat, hand tremors, diarrhea, increased sweating, trouble sleeping, and weight loss. Some people develop abnormal enlargement of the thyroid gland (goiter). Women with Graves' disease may have irregular menstrual periods. In some cases, Graves' disease causes other problems such as Graves�?? dermopathy (a condition marked by red, swollen skin), various eye abnormalities (such as bulging eyes, vision problems, pain, or swelling), emotional or behavioral changes, heart-related complications, or bone problems (such as osteoporosis). Treatment for hyperthyroidism and its symptoms may include radioiodine therapy, antithyroid drugs, and/or thyroid surgery. Most people eventually develop hypothyroidism after treatment for hyperthryoidism; this is treated with a daily synthetic thyroid hormone pill. Graves' dermopathy may be treated with corticosteroids and/or compression wraps. Eye problems may not improve after thyroid treatment and may be treated separately with eyedrops, rituximab, or rarely, surgery or radiation therapy.

MalaCards based summary : Graves' Disease, also known as graves disease, is related to graves disease 1 and hyperthyroidism. An important gene associated with Graves' Disease is TSHR (Thyroid Stimulating Hormone Receptor), and among its related pathways/superpathways are Autoimmune thyroid disease and Cytokine Signaling in Immune system. The drugs Propylthiouracil and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include thyroid, eye and skin, and related phenotypes are endocrine/exocrine gland and hematopoietic system

Disease Ontology : 12 An autoimmune disease of endocrine system that involves production of excessive amount of thyroid hormones, located in thyroid gland.

Genetics Home Reference : 25 Graves disease is a condition that affects the function of the thyroid, which is a butterfly-shaped gland in the lower neck. The thyroid makes hormones that help regulate a wide variety of critical body functions. For example, thyroid hormones influence growth and development, body temperature, heart rate, menstrual cycles, and weight. In people with Graves disease, the thyroid is overactive and makes more hormones than the body needs. The condition usually appears in mid-adulthood, although it may occur at any age.

Wikipedia : 76 Graves'' disease, also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid.... more...

Related Diseases for Graves' Disease

Diseases in the Graves' Disease family:

Graves Disease 1 Graves Disease 2

Diseases related to Graves' Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 409)
# Related Disease Score Top Affiliating Genes
1 graves disease 1 33.9 DIO2 GRD1 SERPINA7 TG TPO TSHR
2 hyperthyroidism 32.2 CTLA4 LMOD1 SERPINA7 TG TPO TSHR
3 thyroiditis 31.2 CTLA4 PTPN22 SERPINA7 TG TPO TSHR
4 goiter 31.2 SERPINA7 TG TPO TSHR
5 myxedema 31.0 CTLA4 TG TPO TSHR
6 multinodular goiter 30.8 TG TPO TSHR
7 plummer's disease 30.8 ICAM1 TG TPO
8 nodular goiter 30.8 ICAM1 TG TPO TSHR
9 hypothyroidism 30.8 CTLA4 DIO2 SERPINA7 TG TPO TSHR
10 subacute thyroiditis 30.7 SERPINA7 TG TPO TSHR
11 struma ovarii 30.7 TG TSHR
12 papillary carcinoma 30.6 TG TPO TSHR
13 myasthenia gravis 30.6 CTLA4 IFNG IL4
14 celiac disease 1 30.3 CTLA4 HLA-DQA1 IFNG PTPN22 TG TPO
15 nontoxic goiter 30.3 SERPINA7 TG TPO TSHR
16 thyroid cancer, nonmedullary, 2 30.2 DIO2 LMOD1 TG TPO TSHR
17 hashimoto encephalopathy 30.2 TPO TSHR
18 neonatal hypothyroidism 30.2 TG TPO TSHR
19 benign struma ovarii 30.2 TG TSHR
20 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.2 CTLA4 IFNG PTPN22 TG TPO TSHR
21 differentiated thyroid carcinoma 30.1 TG TPO TSHR
22 uveitis 30.0 CTLA4 ICAM1 IFNG IL2RA IL4
23 congenital hypothyroidism 30.0 SERPINA7 TG TPO TSHR
24 goiter, multinodular 1, with or without sertoli-leydig cell tumors 29.9 TG TPO
25 hashimoto thyroiditis 29.9 CD40 CTLA4 ICAM1 IFNG IL2RA IL4
26 autoimmune disease 29.9 CD40 CTLA4 FCRL3 HLA-DQA1 IFNG IL2RA
27 multiple sclerosis 29.9 CD40 CTLA4 FCRL3 ICAM1 IFNG IL2RA
28 toxic diffuse goiter 29.9 DIO2 SERPINA7 TG TPO TSHR
29 rheumatoid arthritis 29.9 CTLA4 FCRL3 HLA-DQA1 ICAM1 IFNG IL2RA
30 systemic lupus erythematosus 29.8 CD40 CTLA4 FCRL3 HLA-DQA1 ICAM1 IFNG
31 vogt-koyanagi-harada disease 29.8 HLA-DQA1 IL2RA PTPN22
32 hypothyroidism, congenital, nongoitrous, 2 29.8 SERPINA7 TG TSHR
33 hyperthyroxinemia 29.8 SERPINA7 TPO TSHR
34 keratoconjunctivitis 29.8 ICAM1 IFNG IL4
35 alopecia areata 29.8 CTLA4 HLA-DQA1 ICAM1 IFNG IL2RA PTPN22
36 diabetes mellitus, insulin-dependent 29.4 CTLA4 HLA-DQA1 IFNG IL2RA IL4 PTPN22
37 graves disease x-linked 1 12.2
38 graves disease 2 12.2
39 pediatric-onset graves disease 12.1
40 exophthalmos 11.4
41 digeorge syndrome 11.3
42 thyrotoxic periodic paralysis 1 11.3
43 thyrotoxic periodic paralysis 2 11.3
44 endocrine exophthalmos 11.3
45 autoimmune thyroid disease 3 11.1
46 myopathy - thyrotoxic 11.1
47 velocardiofacial syndrome 11.0
48 autoimmune thyroid disease 2 11.0
49 hyperthyroidism, nonautoimmune 11.0
50 thyrotoxic exophthalmos 11.0

Graphical network of the top 20 diseases related to Graves' Disease:



Diseases related to Graves' Disease

Symptoms & Phenotypes for Graves' Disease

MGI Mouse Phenotypes related to Graves' Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.07 CD40 CTLA4 DIO2 HLA-DQA1 ICAM1 IFNG
2 hematopoietic system MP:0005397 9.97 CD40 CTLA4 HLA-DQA1 ICAM1 IFNG IL16
3 digestive/alimentary MP:0005381 9.92 CTLA4 DIO2 ICAM1 IFNG IL2RA IL4
4 homeostasis/metabolism MP:0005376 9.73 CD40 CTLA4 DIO2 ICAM1 IFNG IL2RA
5 immune system MP:0005387 9.44 CD40 CTLA4 HLA-DQA1 ICAM1 IFNG IL16

Drugs & Therapeutics for Graves' Disease

Drugs for Graves' Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propylthiouracil Approved, Investigational Phase 4,Phase 3,Phase 2 51-52-5 657298
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
4
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
6
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
7
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
8
Iodine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 7553-56-2 807
9
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
10
Acetylcholine Approved Phase 4,Phase 2,Phase 3 51-84-3 187
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1 50-02-2 5743
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1 1177-87-3
13
Methimazole Approved Phase 4,Phase 1,Phase 2,Not Applicable 60-56-0 1349907
14
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
15
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
16
Propranolol Approved, Investigational Phase 4,Phase 3,Not Applicable 525-66-6 4946
17
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
18
Bimatoprost Approved, Investigational Phase 4,Phase 3,Early Phase 1 155206-00-1 5311027
19
Dinoprost Approved, Investigational Phase 4 551-11-1 5283078
20
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
21
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1 174722-31-7 10201696
22
Methotrexate Approved Phase 4,Not Applicable 59-05-2, 1959-05-2 126941
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
24
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
25 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Antithyroid Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
29 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
32 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
36 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
38 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Methylprednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
41 Ophthalmic Solutions Phase 4,Phase 2
42 Viscosupplements Phase 4,Not Applicable
43 Adjuvants, Immunologic Phase 4,Not Applicable
44 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
45 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
46 Anesthetics, Local Phase 4,Phase 2,Phase 3,Not Applicable
47 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
48 Proxymetacaine Phase 4
49 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy Unknown status NCT01056419 Phase 4 Propylthiouracil
2 A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy Unknown status NCT01969019 Phase 4 methylprednisolone, prednisone
3 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
4 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease Completed NCT00946296 Phase 4 Potassium Iodide
5 Prevention Relapse of Graves' Disease by Intrathyroid Injection of Dexamethasone Completed NCT00917241 Phase 4 MMI combined with IID;MMI
6 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4 Diclofenac;Methimazole;L-thyroxin;Propranolol;Metoprolol
7 Antithyroid Drugs During Radioiodine Therapy Completed NCT00150137 Phase 4 Methimazole
8 Block-replacement Therapy During Radioiodine Therapy Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
9 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
10 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
11 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
12 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
13 Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Completed NCT01599273 Phase 4 subconjunctival triamcinolone injection
14 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
15 Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Recruiting NCT03107078 Phase 4 Glucocorticoids
16 A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Not yet recruiting NCT03098225 Phase 4 Methylprednisolone
17 Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease Not yet recruiting NCT02339142 Phase 4 intravenous corticosteroids (methylprednisolone)
18 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Withdrawn NCT01927406 Phase 4 Prostaglandin Analog;Timolol
19 Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction Withdrawn NCT01272414 Phase 4 Botulinum Toxin Type A;Saline injection
20 Early Levothyroxine Post Radioactive Iodine Unknown status NCT01950260 Phase 2, Phase 3 Levothyroxine
21 The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions Unknown status NCT01204359 Phase 3
22 Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
23 Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease Unknown status NCT00370734 Phase 2, Phase 3 Botulinum toxin A injection
24 Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism Completed NCT01039818 Phase 3
25 Assessing the Impact of the Early and Systematic Hormonal Replacement After Radio-isotopic Ablation of Graves'hyperthyroïdism on Quality of Life, Efficiency and Tolerance Completed NCT01295333 Phase 3 the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation;The initiation of LT4 as soon as the first biological signs of hypothyroidism.
26 Trial of Rituximab for Graves' Ophthalmopathy Completed NCT00595335 Phase 2, Phase 3 Rituximab;Saline;Methylprednisolone
27 Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues Completed NCT02155049 Phase 3 bimatoprost 0.03%
28 Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed NCT01297699 Phase 3 Tocilizumab (RoActemra®);Sterile 0.9% Sodium Chloride
29 Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism Recruiting NCT03303053 Phase 3 Cholestyramine Powder 4g;Prednisolone;Standard treatment
30 Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy Recruiting NCT03066076 Phase 3 Antithyroid Drug
31 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
32 Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS) Recruiting NCT03131726 Phase 3 Simvastatin 40mg;Diclofenac Potassium 50 MG
33 The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Recruiting NCT01579539 Phase 3 Methylprednisolone;Esomeprazole
34 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study Active, not recruiting NCT03298867 Phase 3
35 Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study Enrolling by invitation NCT03461211 Phase 3
36 The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease Not yet recruiting NCT02422368 Phase 2, Phase 3 Methylprednisolone + ASTED;Methylprednisolone +Placebo
37 The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) Not yet recruiting NCT02393183 Phase 2, Phase 3 ASTED
38 Role of the Microbiome in Graves' Orbitopathy Unknown status NCT02373995 Phase 1, Phase 2
39 Doxycycline Treatment in Mild Graves' Orbitopathy Unknown status NCT02203682 Phase 2 Doxycycline;placebo
40 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients Completed NCT02993302 Phase 2 1α-D3;Placebos
41 A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease Completed NCT02713256 Phase 2 CFZ533
42 Radioactive Iodide Therapy for Pediatric Graves' Disease Completed NCT01269749 Phase 2 ATD Group
43 Rituximab in the Treatment of Graves' Disease Completed NCT00150111 Phase 1, Phase 2 Methimazole;Rituximab
44 rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
45 Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy Completed NCT00424151 Phase 1, Phase 2 Rituximab
46 Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Completed NCT01727973 Phase 1, Phase 2 Doxycycline
47 Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease Completed NCT01868997 Phase 2 teprotumumab;normal saline
48 Celecoxib for Thyroid Eye Disease Recruiting NCT02845336 Phase 2 Celecoxib;artificial tears
49 Effects of Atorvastatin in Graves' Orbitopathy (GO) Not yet recruiting NCT03110848 Phase 2 Atorvastatin;Methylprednisolone
50 A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease Terminated NCT01114503 Phase 2 Otelixizumab - low dose;Otelixizumab - medium low dose;Otelixizumab - medium high dose;Otelixizumab - high dose;Otelixizumab;Methylprednisolone

Search NIH Clinical Center for Graves' Disease

Cochrane evidence based reviews: graves disease

Genetic Tests for Graves' Disease

Genetic tests related to Graves' Disease:

# Genetic test Affiliating Genes
1 Graves Disease 29

Anatomical Context for Graves' Disease

MalaCards organs/tissues related to Graves' Disease:

41
Thyroid, Eye, Skin, Heart, T Cells, Bone, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Graves' Disease:

19
Thyroid Gl

Publications for Graves' Disease

Articles related to Graves' Disease:

(show top 50) (show all 2205)
# Title Authors Year
1
Graves' disease in clinical perspective. ( 30468646 )
2019
2
How does neural monitoring help during thyroid sugery for Graves' disease? ( 30510903 )
2019
3
Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves' disease. ( 29976201 )
2018
4
Administration of thiamazole for Graves' disease might trigger the onset of type 1 diabetes. ( 29900683 )
2018
5
RE: Novel Application of Quantitative Single-Photon Emission Computed Tomography/Computed Tomography to Predict Early Response to Methimazole in Graves' Disease. ( 29354016 )
2018
6
Treatment of Graves' disease in children: The Portuguese experience. ( 29325833 )
2018
7
Exophthalmos in a young woman with no graves' disease - a case report of IgG4-related orbitopathy. ( 29329570 )
2018
8
The Outcome of Papillary Thyroid Cancer Associated with Graves' Disease: A Case Control Study. ( 29854383 )
2018
9
Early Stage Graves' Disease is Uniformly Accompanied by Orbital Immune Activity even in Patients who Fail to Develop Orbithopathy during Follow-up. ( 29388175 )
2018
10
Thyroid Peroxidase Antibody is Associated with Plasma Homocysteine Levels in Patients with Graves' Disease. ( 29966154 )
2018
11
A retrospective cohort study: do patients with graves' disease need to be euthyroid prior to surgery? ( 29784035 )
2018
12
Delusional Psychosis in Graves' Disease. ( 29372940 )
2018
13
Neonatal Thyrotoxicosis with Tricuspid Valve Regurgitation and Hydrops in a Preterm Infant Born to a Mother with Graves' Disease. ( 29736321 )
2018
14
Association of FoxP3 promoter polymorphisms with the risk of Graves' disease in ethnic Kashmiri population. ( 29890310 )
2018
15
Sequential occurrence of Graves' disease and immune thrombocytopenic purpura as manifestations of immune reconstitution inflammatory syndrome in an HIV-infected patient. ( 29361886 )
2018
16
Recurrence of Graves' disease in ectopic thyroid tissue. ( 29367360 )
2018
17
Utility of rituximab treatment for exophthalmos, myxedema, and osteoarthropathy syndrome resistant to corticosteroids due to Graves' disease: a case report. ( 29448964 )
2018
18
A Case of Graves' Disease Accompanied with Acute Hepatitis A Virus Infection. ( 29943563 )
2018
19
Effect of Goiter Dispersion Formula on Serum Cytokines in Hyperthyroidism Patients with Neurologic Manifestations of Graves' Disease: A Randomized Trial on 80 Cases. ( 29406821 )
2018
20
Correction to: Does Surgery Without Lugol's Solution Pretreatment for Graves' Disease Increase Surgical Morbidity? ( 29423741 )
2018
21
Diagnostic accuracy of a new fluoroenzyme immunoassay for the detection of TSH receptor autoantibodies in Graves' disease. ( 29435670 )
2018
22
Incidental thyroid carcinoma in surgery-treated hyperthyroid patients with Graves' disease: a systematic review and meta-analysis of cohort studies. ( 29872340 )
2018
23
Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy. ( 29849043 )
2018
24
Changes in Body Compositions and Basal Metabolic Rates during Treatment of Graves' Disease. ( 29853888 )
2018
25
Pattern of presentation of Graves' disease and response to radioiodine therapy in South African men. ( 29875930 )
2018
26
Graves' disease coexisting with resistance to thyroid hormone: a rare case. ( 29445473 )
2018
27
Cerebral venous sinus thrombosis precipitated by Graves' disease. ( 29866676 )
2018
28
Disease Burden and Outcome in Pediatric and Young Adults with Concurrent Graves Disease and Differentiated Thyroid Carcinoma. ( 29788090 )
2018
29
Decreased Expression of TIM-3 on Th17 Cells Associated with Ophthalmopathy in Patients with Graves' Disease. ( 29974826 )
2018
30
Case report of recurrent atrial fibrillation induced by thyrotropin-secreting pituitary adenoma with Graves' disease. ( 29901603 )
2018
31
Polymorphisms of IKZF3 Gene and Autoimmune Thyroid Diseases: Associated with Graves' Disease but Not with Hashimoto's Thyroiditis. ( 29510406 )
2018
32
<sup>131</sup> I-Induced Graves' disease in patients treated for toxic multinodular goitre: systematic review and descriptive analysis. ( 29353393 )
2018
33
High Serum Fractalkine is Associated with Lower Trabecular Bone Score in Premenopausal Women with Graves' Disease. ( 29954010 )
2018
34
Prolactin-Producing Pituitary Carcinoma, Hypopituitarism, and Graves' Disease-Report of a Challenging Case and Literature Review. ( 29928263 )
2018
35
Comparative assessment of Graves' disease and main extrathyroidal manifestation, Graves' ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue. ( 29915201 )
2018
36
Graves' disease presenting as severe postpartum pruritus. ( 29909393 )
2018
37
Graves' disease. Time to move on. ( 29348117 )
2018
38
Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management. ( 29946800 )
2018
39
Current Diagnosis and Management of Graves' Disease. ( 29950539 )
2018
40
Association of single nucleotide polymorphism in CD28(C/T-I3 + 17) and CD40 (C/T-1) genes with the Graves' disease. ( 29371709 )
2018
41
Graves' disease following allogenic hematopoietic stem cell transplantation for severe aplastic anemia: case report and literature review. ( 29708883 )
2018
42
A case of Graves' disease associated with membranoproliferative glomerulonephritis and leukocytoclastic vasculitis. ( 30226207 )
2018
43
Graves' Disease Presenting as Painful Goiter: A Case Report and Review of the Literature. ( 30101044 )
2018
44
Radioiodine treatment for graves' disease: a 10-year Australian cohort study. ( 30541519 )
2018
45
Thyrotoxicosis in Graves' Disease with Invasive Laryngeal Cancer. ( 29279495 )
2018
46
Graves' disease presenting as life-threatening hypokalaemic periodic paralysis. ( 29285824 )
2018
47
Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction. ( 29288501 )
2018
48
Does Surgery Without Lugol's Solution Pretreatment for Graves' Disease Increase Surgical Morbidity? ( 29302725 )
2018
49
A preliminary study on the expression and clinical value of platelet-derived growth factor BB, hypoxia inducible factor-1α and C-C motif chemokine receptor-2 in peripheral blood during the pathogenesis of Graves' disease. ( 29319128 )
2018
50
Deep lateral wall orbital decompression following strabismus surgery in patients with Type II ophthalmic Graves' disease. ( 29319400 )
2018

Variations for Graves' Disease

Expression for Graves' Disease

Search GEO for disease gene expression data for Graves' Disease.

Pathways for Graves' Disease

Pathways related to Graves' Disease according to KEGG:

37
# Name Kegg Source Accession
1 Autoimmune thyroid disease hsa05320

Pathways related to Graves' Disease according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.24 CD40 HLA-DQA1 ICAM1 IFNG IL16 IL2RA
2
Show member pathways
12.64 HLA-DQA1 ICAM1 IFNG IL2RA IL4
3
Show member pathways
12.45 CD40 HLA-DQA1 IFNG IL2RA IL4
4 12.31 CD40 HLA-DQA1 ICAM1 IL2RA
5 12.28 CTLA4 IFNG IL2RA IL4 PTPN22
6
Show member pathways
12.25 CD40 CTLA4 HLA-DQA1 IL2RA
7
Show member pathways
12.16 DIO2 ICAM1 IFNG IL4
8
Show member pathways
12.08 CD40 HLA-DQA1 IFNG IL4
9
Show member pathways
12.06 CD40 CTLA4 HLA-DQA1 ICAM1 IFNG IL2RA
10 11.88 ICAM1 IFNG IL4
11
Show member pathways
11.87 ICAM1 IFNG IL16 IL2RA IL4
12 11.86 IFNG IL2RA IL4
13 11.86 CD40 CTLA4 HLA-DQA1 ICAM1
14
Show member pathways
11.84 IFNG IL2RA IL4
15 11.77 HLA-DQA1 IL2RA IL4
16 11.68 ICAM1 IFNG IL4
17 11.66 IFNG IL2RA IL4
18 11.58 CTLA4 HLA-DQA1 ICAM1 IFNG
19 11.57 CTLA4 HLA-DQA1 PTPN22
20 11.56 CD40 IFNG IL4
21
Show member pathways
11.44 CTLA4 IFNG IL2RA IL4
22 11.34 CD40 ICAM1 IFNG
23 11.27 IFNG IL2RA IL4
24 10.78 CD40 IFNG IL2RA IL4
25 10.11 TG TPO TSHR

GO Terms for Graves' Disease

Cellular components related to Graves' Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.1 CD40 FCRL3 ICAM1 IL2RA TPO TSHR

Biological processes related to Graves' Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.92 CD40 CTLA4 HLA-DQA1 IL2RA PTPN22
2 cytokine-mediated signaling pathway GO:0019221 9.81 ICAM1 IL16 IL2RA IL4
3 positive regulation of cold-induced thermogenesis GO:0120162 9.67 DIO2 IL4 TSHR
4 immune response GO:0006955 9.63 CTLA4 HLA-DQA1 IFNG IL16 IL2RA IL4
5 regulation of NIK/NF-kappaB signaling GO:1901222 9.54 PTPN22 UACA
6 interferon-gamma-mediated signaling pathway GO:0060333 9.54 HLA-DQA1 ICAM1 IFNG
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.5 CD40 IFNG IL4
8 negative regulation of immune response GO:0050777 9.48 CTLA4 IL2RA
9 thyroid hormone generation GO:0006590 9.46 DIO2 TPO
10 positive regulation of isotype switching to IgG isotypes GO:0048304 9.43 CD40 IL4
11 positive regulation of B cell proliferation GO:0030890 9.43 CD40 FCRL3 IL4
12 thyroid hormone metabolic process GO:0042403 9.4 DIO2 TG
13 regulation of regulatory T cell differentiation GO:0045589 9.13 CTLA4 IFNG IL2RA
14 hormone biosynthetic process GO:0042446 8.8 DIO2 TG TPO

Sources for Graves' Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....